Discrepancy between subjective and objective cognitive function in multiple sclerosis and association with mood, fatigue, and pain
Multiple Sclerosis Journal - Experimental, Translational and Clinical · Published 2026-04-01 · DOI 10.1177/20552173261449673
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1177/20552173261449673
Abstract
Background Interpretation of cognitive impairment (CI) in persons with multiple sclerosis (PwMS) is limited by discrepancies between objective and subjective evaluation. Objectives Evaluate relationships between subjective and objective cognitive measures, accounting for contributors. Methods Multiple Sclerosis Neuropsychological Questionnaire (MSNQ), patient-reported outcomes, Processing Speed Test (PST), Rey Auditory Verbal Learning (RAVLT), Visual Memory Test (VMT), Face Emotion Recognition (FER), Corsi, and Flanker test scores were collected. Spearman correlations, diagnostic metrics, and latent profile analysis assessed associations and cognitive phenotypes. Results In 83 PwMS, only 4.8–15.7% showed objective domain-specific CI, yet 42.2% reported significant CI. However, 51.8% had objective impairment in ≥1 domain. Compared with PwMS without objective or subjective CI, those with subjective but no objective CI had higher Hospital Anxiety Depression Scale-A (9.92 vs. 4.83) and D (8.23 vs. 2.88), and Fatigue Severity Scale (5.56 vs. 3.80) scores, p < 0.05. Latent profile analysis identified a performant cluster (C1, n = 36) and a less performant cluster (C2, n = 46) with higher mean z-scores on PST (0.46 vs. −0.70), VMT (0.32 vs. −0.54), RAVLT (0.99 vs. −0.06), and FER (0.57 vs. −0.80), p < 0.005, in C1. The MSNQ scores were similar between clusters. Conclusion A discrepancy between subjective and objective CI is observed. Subjective CI is associated with anxiety, depression, and fatigue. Multidomain testing and assessment of contributors may help reconcile this discrepancy.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Related articles
- Comorbidities in newly diagnosed multiple sclerosis patients: A population-based register study in Finland · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Real-world safety and effectiveness of ofatumumab in multiple sclerosis: A clinic-based study in Australia · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Men's health research priorities in men with multiple sclerosis · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Deep cervical lymph node volume decreases following B-cell depletion therapy · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Feasibility and preliminary outcomes of a remotely-delivered exercise training intervention for English-speaking Hispanics/Latinos with multiple sclerosis: Results from the FERLA MS study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Analysis of an innovative fluid biomarker panel for early prediction of progression independent of relapse activity in multiple sclerosis · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal